Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edap TMSFOCL -2.25%56 EV-to-EBIT is -5.84 as of Aug. 10, 2026. GuruFocus rates FOCL with a GF Score™ of 56/100 and a GF Value™ of $4.45 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 96 Medical Distribution companies, Edap TMS ranks worse than 1041665.63% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Edap TMS's Enterprise Value for the quarter that ended in Mar. 2026 was $152.2 Mil.
Edap TMS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edap TMS EV-to-EBIT Related Terms
Edap TMS EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Edap TMS's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Edap TMS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edap TMS EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Edap TMS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Edap TMS's EV-to-EBIT falls into.
Edap TMS's current Enterprise Value is $240.7 Mil.
Edap TMS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edap TMS (FOCL) has a EV-to-EBIT of -5.84 as of Aug. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Edap TMS and its competitors. According to the industry distribution chart, Edap TMS ranks #999999 out of 96 companies in the Medical Distribution industry.
Is Edap TMS's EV-to-EBIT too high?
Edap TMS's current EV-to-EBIT is -5.84. Based on the distribution chart, Edap TMS ranks #999999 out of 96 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Edap TMS has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Edap TMS's EV-to-EBIT compare to ACH and YI?
According to the Medical Distribution industry distribution chart, Edap TMS ranks #999999 out of 96 companies for EV-to-EBIT. This places Edap TMS in the lower half of its industry. The industry median EV-to-EBIT is 11.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.94, based on 96 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Edap TMS and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edap TMS's current EV-to-EBIT is -5.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edap TMS stock overvalued right now?
Based on GuruFocus' analysis, Edap TMS (FOCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.45, compared to a current price of $6.08 — trading 36.6% above its estimated fair value. The current EV-to-EBIT is -5.84. Edap TMS's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Edap TMS (FOCL), the current EV-to-EBIT is -5.84 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edap TMS (FOCL) Overvalued in 2026?
Based on GuruFocus' analysis, Edap TMS stock appears to be overvalued.
The current stock price of $6.08 is trading 36.6% above its estimated GF Value™ of $4.45.
GuruFocus considers Edap TMS to be Significantly Overvalued.
Key valuation signals for FOCL:
EV-to-EBIT: -5.84
GF Value™: $4.45 vs. price of $6.08 (36.6% above fair value)
No single metric tells the full story. See the FOCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
56GF Score
Get the complete analysis for FOCL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FOCL has been successfully added to your 
